Online inquiry

IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4056MR)

This product GTTS-WQ4056MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL36RN gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_012275.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26525
UniProt ID Q9UBH0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4056MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1068MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ4772MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ10887MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ9889MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ8940MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ3387MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ5930MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ2295MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN-1210
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW